Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Ability To Follow Anti-reabsorptive Drug Treatment In Postmenopausal Women With Reduced Bone Mass.|
|Author:||Gomes, Débora Castro|
Farhat, Fátima C L G
Pedro, Adriana O
Pinto-Neto, Aarão Mendes
|Abstract:||Studies show that adherence to osteoporosis treatment and prevention is low, which could interfere with therapeutic response. The aim of this study was to evaluate the ability of women to follow a treatment for osteoporosis with different anti-reabsorptives in relation to the prescribed regimen, dose, indications, and mode of ingestion. A cross-sectional study that included postmenopausal women all undergoing medicated treatment because of densitometric diagnosis of osteopenia or osteoporosis was carried out by means of the MedTake questionnaire. A total of 227 women at a menopause clinic were studied. The following were evaluated: sociodemographic characteristics, other illnesses, use of concomitant medication, use of medication for osteoporosis, length of use, and ability to follow the treatment in relation to the prescribed regimen, dose, indication, and mode of ingestion. The ability to follow the treatment as evaluated by the MedTake was below 80% for most of the women. No significant difference was found between the daily or weekly bisphosphonate users and those taking raloxifene. The factors associated with inadequate treatment were the following: being 70 years or older (odds ratio [OR], 5.62; 95% CI, 1.23-25.64), being illiterate (OR, 10.14; 95% CI, 2.14-48.12), use of other medications (OR, 0.33; 95% CI, 0.15-0.76), and shorter length of use of medication for osteoporosis (OR, 5.67; 95% CI, 2.27-14.16). The ability to follow a treatment involving different anti-reabsorptive medications for osteoporosis is high relative to mode of ingestion, coingestion, and indication and low in relation to knowledge of the correct dose. Low ability is associated with advanced age, being illiterate, not using other medications, and shorter treatment time.|
Bone Density Conservation Agents
|Citation:||Menopause (new York, N.y.). v. 18, n. 5, p. 531-6, 2011-May.|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.